Best GLP-1 Providers in New Jersey (2026)

See by medication

Looking for a specific GLP-1? Browse New Jersey providers by drug.

About GLP-1s in New Jersey

New Jersey allows telehealth GLP-1 prescribing. NJ FamilyCare Medicaid covers GLP-1s for both diabetes and obesity with prior authorization.

• •New Jersey's adult obesity rate is 28.7%
• •NJ FamilyCare covers GLP-1s with prior authorization
• •Newark is a major Northeast telehealth market

Top Cities for GLP-1 Treatment in New Jersey

Telehealth providers ship to all New Jersey addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the New Jersey GLP-1 clinic directory →

GLP-1 Care Access in New Jersey: The Numbers

New Jersey has 1,170 NPI-registered in-person weight-management clinics across 223 cities — 23 with an obesity-medicine taxonomy, 577 endocrinology, and 585 bariatric — alongside 93 telehealth programs that ship to New Jersey addresses. The cheapest verified ongoing compounded semaglutide price available to New Jersey residents is $79/mo (tirzepatide: $104/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in New Jersey

In Q1 2026, New Jersey Medicaid reimbursed approximately $27,380,158 across 28,312 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in New Jersey cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $224/mo.

For the exact criteria, drug list, and appeal process, read our New Jersey Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in New Jersey

According to CDC data, 28.7% of New Jersey adults have obesity (BMI of 30 or higher). This places New Jersey at #42 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping New Jersey residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions